Posted by Michael Wonder on 03 Dec 2021
FDA approves pembrolizumab for adjuvant treatment of stage IIB or IIC melanoma
3 December 2021 - On 3 December 2021, the FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection.
Efficacy was evaluated in KEYNOTE-716, a multicenter, randomised (1:1), double-blind, placebo-controlled trial in patients with completely resected stage IIB or IIC melanoma.
